Evaluating Alpine Immune Sciences: Insights From 6 Financial Analysts

Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on Alpine Immune Sciences ALPN in the last three months.

The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.

Insights from analysts' 12-month price targets are revealed, presenting an average target of $41.5, a high estimate of $50.00, and a low estimate of $32.00. Marking an increase of 51.46%, the current average surpasses the previous average price target of $27.40.

Exploring Analyst Ratings: An In-Depth Overview

In examining recent analyst actions, we gain insights into how financial experts perceive Alpine Immune Sciences. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Alpine Immune Sciences. This insight gives a snapshot of analysts' perspectives on the current state of the company.
• Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Alpine Immune Sciences compared to the broader market.
• Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Alpine Immune Sciences's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.

Capture valuable insights into Alpine Immune Sciences's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.

Stay up to date on Alpine Immune Sciences analyst ratings.

Delving into Alpine Immune Sciences's Background

Alpine Immune Sciences Inc is a clinical-stage biopharmaceutical company dedicated to discovering and developing protein-based immunotherapies to treat autoimmune and inflammatory diseases. Its approach includes a proprietary scientific platform that converts native immune system proteins into differentiated, multi-targeted therapeutics. Its pipeline candidates are; ALPN-303, or povetacicept, is a dual antagonist of the B cell activating factor, or BAFF, and a proliferation-inducing ligand, or APRIL, cytokines, which play key roles in the activation, development, and survival of B cells, and ALPN-101, or acazicolcept, is a dual Inducible T cell Costimulator, or ICOS, and CD28 antagonist intended for the treatment of autoimmune and inflammatory diseases.

Unraveling the Financial Story of Alpine Immune Sciences

Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.

Revenue Growth: Alpine Immune Sciences's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2023, the company achieved a revenue growth rate of approximately 20.03%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.

Net Margin: Alpine Immune Sciences's net margin is impressive, surpassing industry averages. With a net margin of -116.72%, the company demonstrates strong profitability and effective cost management.

Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -7.08%, the company may need to address challenges in generating satisfactory returns for shareholders.

Return on Assets (ROA): Alpine Immune Sciences's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -4.75%, the company may encounter challenges in delivering satisfactory returns from its assets.

Debt Management: Alpine Immune Sciences's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.06.

Analyst Ratings: What Are They?

Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.

In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.

This article was generated by Benzinga's automated content engine and reviewed by an editor.